Diabetics and cardiovascular disease sufferers around the world will soon benefit from a revolutionary skin treatment developed by Dr. Brian Ward of Ngati Porou.
Dr Brian Ward is driven by a passion to make a positive impact on people’s health care. He is the founder of soft tissue reconstruction company Mesynthes. The young, gifted and brown (YGB) entrepreneur has developed a technology called Endoform extra cellular matrix (ECM), a protein framework which provides an environment for cells to grow in. Over time the matrix is broken down by the cells and is turned into the patient’s own tissue.
To read this article click here
Key quotes from article:
“As diabetics and cardiovascular sufferers get older they develop wounds which the body finds difficult to heal. Dr Ward says it’s a major problem throughout the world. In the United States alone there are 21 million diabetics. Of these, around 15% develop Diabetic Foot Ulcers (DFU’s). Up to 30% percent of these wounds do not heal satisfactorily with traditional treatment and become chronic. “The technology provides a way of healing very large wounds and tissues that have been severely damaged,” says Dr Ward.”
“Mesynthes has established a manufacturing facility which includes processing and clean room areas with a capacity to meet early market demand. Mesynthes raised initial capital for the company in late 2007 from angel investors Movac, Sparkbox and the New Zealand Venture Investment Fund. The company was subsequently awarded a significant technology development grant by the Foundation for Research Science and Technology. These funds have been applied to technology development and gaining US registration of its lead wound care product. Dr Ward is confident the work Mesynthes has done in pre clinical testing trials will show how the ECM platform is more effective and has more positive effects than the current leading product in the US.”
Loading...
